Stockscreener 앱 받기
1.20
0.84%
0.01
전일 마감가:
$1.19
열려 있는:
$1.2
하루 거래량:
74,960
Relative Volume:
1.01
시가총액:
$32.88M
수익:
-
순이익/손실:
$-37.38M
주가수익비율:
-0.962
EPS:
-1.2474
순현금흐름:
$-35.50M
1주 성능:
+9.09%
1개월 성능:
+1.69%
6개월 성능:
+6.19%
1년 성능:
-18.92%
1일 변동 폭
$1.16
$1.23
1주일 범위
$1.05
$1.23
52주 변동 폭
$1.01
$1.55
An 2 Therapeutics Inc Stock (ANTX) Company Profile
명칭
An 2 Therapeutics Inc
전화
(650) 331-9090
주소
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
ANTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.20 | 32.61M | 0 | -37.38M | -35.50M | -1.2474 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2024-08-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-12 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 개시 | JMP Securities | Mkt Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
모두보기
An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스
Sionna Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with - The Manila Times
This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street - Yahoo Finance
Dyne Therapeutics Announces Positive Topline Results from - GlobeNewswire
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - MarketScreener
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView
Akebia Therapeutics, Inc. Initiates Phase 2 Clinical Trials for the Treatment of Focused Segmental Glomerulosclerosis Using Praliciguat - marketscreener.com
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS - MarketScreener
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
Protara (Nasdaq: TARA) Sees 100% Success in TARA-002 Pediatric LM Phase 2 Study - Stock Titan
Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women's Health - PR Newswire
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis - Business Wire
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease - GlobeNewswire
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis - Yahoo Finance
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRCSlideshow (NASDAQ:XLO) 2025-11-11 - Seeking Alpha
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - Yahoo Finance
Intellia Therapeutics Presents Positive Pooled Phase 1/2 - GlobeNewswire
Cadrenal Therapeutics, Inc. - TradingView
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for - GlobeNewswire
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart - Business Wire
Relmada (NASDAQ: RLMD) posts 92% ORR in NMIBC as FDA supports two Phase 3 paths - Stock Titan
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo - Business Wire
Rein Therapeutics (NASDAQ: RNTX) to resume Phase 2 IPF trial; U.S. enrollment at 20 sites - Stock Titan
Beam Therapeutics to Present Updated Data from BEACON Phase - GlobeNewswire
2,541,781 Restricted Stock Units of Cognition Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-NOV-2025. - MarketScreener
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock - PR Newswire
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewswire
Intensity Therapeutics surges 395% on phase 1/2 data for solid tumors asset - Seeking Alpha
KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - Yahoo Finance
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to - GlobeNewswire
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules - Business Wire
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics
BlossomHill Therapeutics Presents Preliminary Findings from - GlobeNewswire
Tango Therapeutics Reports Positive Data from Ongoing Phase - GlobeNewswire
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - Yahoo Finance
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 - Yahoo Finance
Perspective Therapeutics Reports 44% ORR in Cohort 2 | CATX Stock News - Stock Titan
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) - The Manila Times
RAPT Therapeutics to Report Topline Data from Phase 2 - GlobeNewswire
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting - Yahoo Finance
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 - BioSpace
Monopar Therapeutics Inc. Announces Oral Presentation at AASLD 2025 for Phase 2 Study on Tiomolybdate Choline in Wilson Disease - Quiver Quantitative
Tvardi Therapeutics, Inc. Updates on Phase 2 REVERT Trial Results - TradingView
Denali Therapeutics Announces FDA Review Extension of BLA - GlobeNewswire
An 2 Therapeutics Inc (ANTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):